awmsg logo



aflibercept (Eylea®)


Reference No. 1586

Publication date:
14/03/2017


Appraisal information

aflibercept (Eylea®) 40 mg/ml intravitreal injection


Company: Bayer Healthcare Pharmaceuticals
BNF category: Eye
NMG meeting date: 11/01/2017
AWMSG meeting date: 15/02/2017
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 0117
Ministerial ratification: 14/03/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA486) NICE GUIDANCE ISSUED NOVEMBER 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download